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SUMMARY 
Background: Sickle cell disease (SCD) is common in 
Sierra Leone although its exact prevalence, incidence 
and clinical spectrum are unknown.  
Methods: Using a statistical package, StatsDirect (Al-
trincham, United Kingdom) we analyzed the demo-
graphic characteristics, presentations, acute events, 
treatments and clinical outcomes in a cohort of SCD 
patients attending sickle cell clinics in Freetown, Sierra 
Leone between February 2007 and August 2010. 
Results: There were 446 patients, median age of 13 
years. Of these, 435 were homozygotes (HbSS), medi-
an age 13 years also. There were 248 females, median 
age 12.5 and 198 males, median age 14, resulting in a 
male:female ratio of 0.79. Eleven (2.4%) were Sickle 
Cell-HbC disease, median age 14 years. Patients 
demonstrated many of the typical features of SCD. The 
most common reason for hospital admission was bone 
pain crisis associated with an infection, followed by 
severe anemia. Aseptic necrosis of the femoral head, 
leg ulcers, septic osteomyelitis and gallstones were 
seen in 0.22% of patients, but strokes and acute chest 
syndrome were not observed. The death rate was 
2.51/100 patient years observation with an estimated 
mean survival of 3.6 years (CI 3.2-3.7). Severe anemia 
was implicated in the death of 8 patients (50%), where-
as only 2 deaths (12.5%) were attributable to bone pain 
crisis. One death (6.25%) was associated with pregnan-
cy complicated by severe anemia and another with an 
adverse blood transfusion event.  
Conclusion: The clinical outcomes in this series high-
light the need for a more comprehensive provision of 
care for SCD patients in Sierra Leone. 
 







One hundred years ago, Dr J.B. Herrick, a physician 
practicing in the American city of Chicago, published 
the first description of sickle cell disease (SCD) in the 
western medical literature.1 His patient, Walter Clem-
ent Noel, a native of the West Indian Island of Grenada 
had been a student at the city’s College of Dental Sur-
gery between the years 1904 and 1907. In the century 
since that first report, a considerable body of 
knowledge has been amassed on the biology, epidemi-
ology, management and treatment of SCD throughout 
many regions of the world. However, even though Si-
erra Leone lies within the equatorial belt in Africa, 
where the highest estimates of the sickle gene have 
been recorded, 2 very little information on the disease 
has been published from the country. The only signifi-
cant work in the century since Herrick’s first report 
was that of Knox-Macaulay who, in 1983, published 
his observations on a series of 121 Sierra Leonean pa-
tients whom he had been following prospectively.3  
 
One hundred and six of Knox-Macaulay’s patients 
were homozygous SCD (HbSS) with a small minority 
of 15 (12.4%) sickle cell/hemoglobin C or HbSC dis-
ease. Interestingly, Knox-Macaulay observed that 55% 
of his patients were descendants of African slaves who 
had regained their freedom and had been repatriated 
from North America and the West Indies, as well as 
others directly from other countries in Western Africa 
who had been liberated from ships that were taking 
them across the Atlantic Ocean to slavery.4 These freed 
slaves were all landed at the port of Freetown, now the 
capital city of Sierra Leone. It goes without saying, 
therefore, that the descendants of those freed slaves, 
who are now called “Creoles,” but more correctly, 
“Krios,”5 have strong ethnic and genetic relationships 
with Black West Indians and African-Americans, clos-
ing the circle back to that foundation paper by Dr Her-











Ethnic diversity is of course an important factor in un-
derstanding some of the clinical aspects of SCD be-
cause haplotype diversity, occurring among ethnic 
groups can distinguish one community of sickle gene 
carriers from another .6 By the same token, this type of 
diversity can mediate clinical manifestations of the 
disease, for better or for worse.7 Notwithstanding this, 
however, it was not surprising that Knox-Macaulay 
was unable to detect any significant clinical differences 
between Sierra Leonean “Creoles” and “non-Creoles.” 
It is not surprising because of a number of reasons. 
Firstly, the numbers were too small for statistical pow-
er to accrue in the cohort. Secondly, the Creole ethnic 
group is extremely diverse in its African, Afro-
American and Afro-Caribbean origins as we have al-
ready seen.5 Slaves, landed in the West Indies and 
America came from a variety of African sources.8  
 
Some of those who were taken to America, in particu-
lar, came originally from the Sierra Leone hinterland.9 
Those who had come from elsewhere would have, in-
evitably, during the hundred or so years before eventu-
al repatriation to Sierra Leone, inter-married, not only 
among themselves, but probably also with slaves who 
had been taken directly from Sierra Leone. Further 
diversity in the Creole group would have occurred, as 
explained previously, as a result of individuals intro-
duced into the early community directly from various 
West African sources (including Sierra Leone) during 
the early to mid-nineteenth century.9 This latter group 
of “liberated Africans” as they were called, eventually 
integrated and intermarried with the returnees from 
across the Atlantic Ocean, and indeed other Sierra Le-
oneans.9  
 
When Knox-Macaulay compared Sierra Leone sickle 
cell patients with other groups of sickle cell patients 
elsewhere in the world, both similarities and diver-
gences were observed. For example, vaso-occlusive 
events were similar to those in American, Jamaican, 
Ghanaian and Nigerian patients. 10,11 And whereas the 
frequency of leg ulceration in Sierra Leonean sickle 
cell patients was relatively low (13.2% SS, 13.3% SC) 
when compared to patients in the United States (73.6% 
SS) and Jamaica (63.3% SS), it was relatively high in 
comparison to Nigerian and Ghanaian patients.  
 
On the other hand, avascular necrosis of the femoral 
head (ANFH) was more common among Sierra Leone-
an patients as a whole (8.5% SS, 20% SC) than in 
Ghanaians (2.8% SS, 6.6% SC), although similar to 
frequencies in Jamaican patients (8.2% SS, 18% SC).   
 
 
Although Knox-Macaulay considered that these differ-
ences in complication rates could probably be attribut-
ed to environmental factors, they are only likely to be 
fully understood if haplotype and other biological ele-
ments are factored in. 
 
As far as environmental factors go, they not only influ-
ence clinical outcomes but, at least one, malaria, in 
addition to potentially provoking acute painful epi-
sodes in the sickle cell patient, underpins the high 
prevalence rates the sickle gene demonstrates wherever 
it occurs.12 Half a century after Herrick’s report, it was 
hypothesized that the high prevalence of beta-
thalassemia trait was the result of a balance between 
the red cell abnormality and Plasmodium falciparum 
malaria.13 This hypothesis was subsequently extended 
to include other red blood cell polymorphisms among 
which, HbS is preeminent.14  
 
The protection against severe malaria that the sickle 
trait (AS) and other mild RBC abnormalities afford 
provides a survival advantage for individuals who carry 
them.15 Consequently, the hypothesis goes, individuals 
who carry the traits enjoy a relatively robust resistance 
to malaria and survive to adulthood, whilst homozy-
gotes, on the other hand, die early, succumbing to a 
variety of environmental challenges.16 In Sierra Leone, 
where P. falciparum malaria is hyperendemic, 17  it can 
be expected, therefore, that the prevalence of the sickle 
gene would be high.  
 
Two reports, one in the mid-fifties and the other, four 
decades later, examined the prevalence of the trait 
among blood samples in two separate series. In the 
earlier report, Rose and Suliman examined the preva-
lence of sickle cell trait (SCT) among individuals of the 
Mende ethnic group, 18whilst in the later publication 
Wurie et al reported a sickle cell positive rate of 22% 
among 3274 sodium metabisulfite-tested specimens 
processed in their laboratory during the early 1990’s.19   
 
Although these reports are useful, they do not, howev-
er, address some of the important questions about prev-
alence among communities in Sierra Leone. Nor do 
they begin to tackle the magnitude of the SCD burden 
and its consequences among Sierra Leoneans. Moreo-
ver, the only report focusing on clinical features was 
published in 1983.3 The rationale for undertaking this 
study, therefore, is to update information about the 
disease in Sierra Leone and to re-evaluate its clinical 
features in patients in this country. Furthermore, a 
study such as this could provide a basis for greater in-














The patients in this study were registered at the clinics 
of the Sierra Leone Sickle Cell Society (SLSCS) in 
Freetown, from 1st February, 2007 to 31st August 2010. 
Patients consisted predominantly of children under the 
age of 18 years. At the clinics, they received intensive 
counselling about the nature of SCD and its complica-
tions and how to prevent and manage crises. In addi-
tion, they were given basic medications to assist nutri-
tion (folic acid) and prevent complications (Penicillin 
V, Amoxicillin). Anti-malaria prophylaxis is provided 
with weekly Pyrimethamine supplemented with advice 
to sleep inside an insecticide-treated bed net. Painful 
crises, when mild, were managed at home and at the 
clinics with mild analgesics including Paracetamol, 
Ibuprofen and Diclofenac plus oral rehydration solu-
tions.  
 
Patients with complicated and more severe pain, not 
controlled by these measures, were referred on to hos-
pital for more intensive care. Other symptoms that 
could not be managed at the clinics were also referred 
to hospital. Patients were followed up on regular 
monthly visits, and non-attendance at specified ap-
pointments was investigated by mobile telephone and, 
where feasible, home visits to patients who continue 
not to show up.  
 
Procedures 
We retrieved the records of patients in the clinics of the 
SLSCS and extracted the demographic data of date of 
registration, age first seen at the clinics, gender, clinical 
features and date of death and age at death. The data on 
hemoglobin phenotype, determined by alkaline elec-
trophoresis on cellulose acetate medium was also ex-
tracted. Data of ethnic group, as reported by the patient 
or parent, was also obtained. Records of landmark clin-
ical events as well as reasons for onward referral were 
also retrieved. Causes of death were evaluated from 
clinical observations in the terminal events that preced-
ed death.  
 
Statistical analysis 
Retrieved data was analyzed using the statistical pack-
age Stats Direct (Altrincham, United Kingdom, WA14 
4QA) that provided descriptive characteristics as well 
as survival analysis. ANOVA was used to compare 
ages of the various categories of patients and survival 
characteristics were estimated by the Kaplan-Meier 
method. Start date of analysis was taken as the date at 
which the patient was registered. All surviving patients 




There were 446 patients, representing 637 patient-
years. The median age of the entire cohort was 14 
years. The demographic data of age, gender and ethnic 
distributions are shown in Tables 1-3 and in Figure 1.  
	
Figure 1 Age structure of Sickle Cell Disease Patients 
in Sierra Leone 
 
Table 1 Sex and Age distribution of Sickle Cell Dis-
ease Patients 
Phenotype Number Percent Median Age (years) 
All SCD Patients 446  14 
All SCD – Females 248 55.6 13 
All SCD – Males 198 44.4 14 
 
Table 2 Sex and age distribution of HbSS and HbSC 
Patients 
 Number Percent Median Age (years) 
SS only 435 97.5 13 
Female 240 55.2 12.5 
Male 195 44.8 14 
HbSC 11 2.5 14 
Female 7 63.6 - 
Male 4 33.4 - 
 
Table 3 Distribution by Tribe compared with Census 
Distribution 
Ethnic Group Number Percentage Census Percentages 
TEMNE 102 30 30 
MENDE 51 15 30 
KRIO 44 13 10 
OTHERS 40 12 30 
 
Homozygous sickle cell disease (HbSS) constituted the 
vast majority of patients, accounting for 435 (97.5%), 
whilst HbSC disease, the only other phenotype detect-
ed consisted of only 11 patients.  ANOVA was used to 
compare the ages among all patient categories but no 
significant differences were revealed. Also, we could 
not detect any differences in ethnic distribution be-
tween HbSS and HbSC patients. 
 
Clinical features  
Clinical features encompassed some of the typical 
complications of SCD, with painful crises being the 
most frequent departures from the steady state.  For the 
twelve month period when adequate figures were 
available, 48 (10.8%) patients required hospital admis-
 
 







sion. Of these, 16 were children under 10 years of age. 
Most admissions were for painful crises, associated 
with an infection episode.  
 
Causes of the infection were not determined although 
some were attributed to malaria. However, 13 patients 
were admitted because of severe anemia. Three pa-
tients underwent surgical procedures, of which 2 were 
Caesarean sections. The third was for drainage of sep-
tic osteomyelitis. The organism involved was not de-
termined. Thirteen patients received non-elective in-
patient blood transfusion. One case each, of ANFH and 
leg ulcers, were observed.  
 
There were no cases of stroke in the series, although 1 
patient (0.22%) had neuropsychiatric disorder that im-
paired his societal interactions. One patient (0.22%) 
reported gallstones which she passed per rectum and an 
adolescent male reported priapism. Three pregnancies 
were recorded, one of which resulted in maternal and 
foetal death (33.3% mortality).  
 
Survival  
The majority of patients continue to live relatively ac-
tive lives, attending school and, for adults, holding 
down jobs. However, a total of 16 (3.6%) patients have 
died, all with HbSS phenotype. The age at death ranged 
from 7-27 years, with a median of 17 years. Using the 
date of first registration as base, an attempt was made 
to calculate survival by Kaplan-Meier analysis (Figure 
2), but the median survival (ordinate, in days) was too 
extended to be determinable. The mean incidence of 
death, however, was 2.51 per 100 patient-years. Esti-




Figure 2 Survivals in 446 Sickle Cell Disease Patients 
 
Causes of Death 
The causes of death were not easy to determine. There 
were no autopsies. However, based on clinical events 
immediately preceding the deaths, causes of death were 
assigned, as indicated in Table 4 in which patients are 
identified by their unique patient numbers*. Signifi-
cantly, 8 patients (50%) died of complications associ-
ated with severe anaemia and one patient (6.25%) had 
an adverse transfusion incident consistent with over-
transfusion and/or haemolytic reaction during treatment 
for severe anaemia, and another patient died with 
anaemia complications associated with pregnancy.  
 
Table 4 Causes of Death 
Patients* Age  Sex Survival Cause of Death 
185 18 F 398 Severe anaemia 
97 7 M 361 Unknown 
254 3 M 493 Unknown 
37 12 F 1064 Unknown  
84 16 M 351 Severe anaemia  
42 19 F 616 Bone pain crisis 
175 11 M 595 Severe anaemia 
85 7 M 569 Unknown 
142 26 M 326 Bone pain crisis  
199 9 M 342 Unknown 
64 6 F 817 Severe anaemia 
87 10 M 161 Severe anaemia 
48 19 M 1029 Unknown 
41 20 F 449 Pregnancy & anaemia 
144 19 F 623 Severe anaemia 
7 27 F 1141 Transfusion incident 
 
DISCUSSION 
The prevalence and incidence of SCD in Sierra Leone 
is unknown. However, based on limited survey results, 
the frequency of the trait is probably in the region of 
about 20-25%, 18,19 which would result in approximate-
ly 10-16 SS cases per 1000 live births annually. Using 
this figure and an estimated population of 6.4 million, 
20 and with an annual birth rate of 44.7/1000, 20 it is 
likely that between 2816 and 4400 HbSS babies are 
born every year. To this should be added babies that 
are compound heterozygotes, the incidence of which is 
entirely unknown. However, their number is not likely 
to be less than 344 and could exceed 546, using data 
from Knox-Macaulay.3  
 
Thus, the total number of new additions of sickle cell 
haemoglobinopathy to the population could be in the 
region of 3160 to 4946 annually. Determination of how 
many of these newborns survive to beyond 5 years 
could be fraught with difficulty as has been noted 
elsewhere.21 However, subtracting the under-fives in-
fant mortality of 154/1000 live births reported for Sier-
ra Leone, 20 will result in a survival of between 3006 
and 4792 babies. These numbers will add to their pre-
decessors already surviving in the population. Deter-
mination of this cumulative number is, again, difficult21 
and only a well-structured population survey can eluci-
date it.  
However, it can be assumed that this number is proba-
bly in the tens of thousands per generation, even if sub-
sequent cumulative mortality is huge.     
 
 








The patients we present in the current study, therefore, 
are likely to represent only a tiny fraction of SCD pa-
tients in the country. With that caveat, the cohort illus-
trates a number of features. Firstly, it confirms that 
HbSS disease predominates, although in this series, the 
proportion of the only other phenotype, HbSC, was, at 
2.5%, smaller even than the 12.4% that Knox-
Macaulay had observed in 1983.3 Then, as in the cur-
rent series, no other phenotypes were observed.  
 
The reason for this is not known, but, in our view, is 
likely to be due to technical factors because, the only 
procedure applied for diagnosis is cellulose acetate 
electrophoresis, in which other variants could be 
missed. There is anecdotal evidence, however, of the 
presence of compound heterozygotes for beta-
thalassemia (HbS Beta-thalassemia) in at least 2 unre-
lated Sierra Leonean families, diagnosed elsewhere. 
Furthermore beta-thalassemia trait frequencies of 9% 
have been reported from Liberia, with which Sierra 
Leone shares its eastern border.21  
 
Another possible reason that could account for the ap-
parent paucity of phenotypes other than HbSS is that 
other phenotypes may be milder than HbSS and there-
fore, do not seek medical attention or may get their 
treatment and management advice from traditional 
providers. The age structure of the cohort (Figure 1) is 
interesting in that median age is only 14 years, com-
pared to 17 for the population at large.20 This finding 
suggests that survival beyond childhood may be rela-
tively reduced among SCD patients, as has been well-
recognized elsewhere.23  
 
This interpretation is reinforced by the fact that under 
14’s represent more than 59% of the group, in contrast 
to only 44.5% in the general population.20 However, 
these observations should be interpreted with caution, 
as it is possible that older patients do not present them-
selves for a variety of reasons, one of which is that 
older, surviving patients may have milder disease and 
so do not seek medical attention.  
 
The ratio of male to female is massively against males 
(198:248, or 0.79). In the general population this ratio 
is about 0.9 in the age sector under consideration.20 The 
cause for this disparity is unknown. When Knox-
Macaulay published his series in 1983, he observed 
that the Krios predominated over the other ethnic 
groups.3The proportions are reversed in the current 
series (Table 3), consistent with a demographic shift in 
this part of the country. In any case, the country-wide 
distribution of ethnic groups currently stands at, Temne 
30%, Mende 30%, Krio 10% and other 30%.20 Our 
series reflects these current trends, certainly with re-
spect to Temnes and Krios. On the other hand, the situ-
ation in other parts of the country, where ethnic distri-
bution may be more homogenous, is unknown. This is 
an important point to unravel, because provision of 
sickle cell care services in the future would depend 
partly on disease prevalence within communities.20  
 
Clinical manifestation of SCD in the current series in-
dicates that some features are not as severe or frequent 
as reported from other countries and indeed, in Knox-
Macaulay’s series. For example, ANFH was seen in 
only one patient (0.22%), contrasting with a 2.9% inci-
dence reported from elsewhere in Africa.24 However, 
apart from symptoms or physical signs, no systematic 
imaging techniques were used to assess the presence of 
hip joint disease. It would be important to ascertain the 
rarity of ANFH in this and similar groups of patients 
and to determine what underlies it.  
 
Leg ulcers were also uncommon among our patients. 
Only one patient, a 19 year-old HbSS male had this 
complication, equivalent to a rate of only 0.16 per 100 
patient years of observation, unlike elsewhere in Afri-
ca.25  Here again, the reason for this rarity is unclear.  
Gallstones, detected by imaging techniques, have 
shown, depending on age, prevalences as high as 58% 
in series from Jamaica, for example,26 although they 
appear less frequent in African series.27 In ours, where 
imaging techniques were not used, we observed only 1 
case, in a 25 year old female, who passed the stone per 
rectum, without symptoms. Clearly, this is an area that 
needs further investigation. 
 
The reasons why patients were admitted to hospital 
varied, but the most common was for pain crisis asso-
ciated with a febrile episode. Although some of these 
patients reportedly had malaria, the causes for fever in 
others were not determined. Neither was the causative 
organism identified in the single patient with septic 
osteomyelitis. Bacteriological cultures were not availa-
ble. Lack of microbiological detail is a major defect in 
our programme, since infection is a recognized risk 
factor for morbidity and mortality in SCD. For exam-
ple, malaria was a principal cause for morbidity in 
Kenyan SCD patients.28 On the other hand, the organ-
isms involved in bacterial sepsis remain a cause for 
debate probably because of the lack of adequate identi-
fication procedures.29 This is another area of research 
that requires attention.  
 
In Nigeria, neurological incidents have been reported 
in varying frequencies among patients with SCD. For 
example, Fatunde et al, in Ibadan, found that, over a 15 
year period, 5.4% of under-6 year-olds attending a 
 
 







sickle cell clinic developed strokes.30 Therefore, the 
absence of overt stroke in our series is surprising alt-
hough a single case of neuropsychiatric disorder was 
observed in our patient with bilateral ANFH. It may be 
that stroke-affected patients are seen at stroke clinics 
elsewhere, where they receive treatment and follow-up.  
 
But an alternative reason might be that SCD patients 
with stroke may have had severe disease to which they 
had succumbed before having an opportunity to present 
at out clinics. No systematic study of potential neuro-
logical impairment either by Doppler and/or by formal 
neuropsychiatric testing has been undertaken, nor were 
we able to conduct imaging studies such as CTI or 
MRI that could have revealed asymptomatic neurologi-
cal lesions.  
 
Some patients presenting with severe anemia required 
emergency blood transfusion usually attended by crises 
in blood procurement. When such crises were resolved, 
the clinical outcome was mainly satisfactory. However, 
in other instances, lack of appropriate blood apparently 
contributed to a fatal outcome. In one case, in contrast, 
a serious transfusion reaction was apparently a contrib-
utory factor to a fatal outcome in a 27 year-old female.  
 
Sickle cell disease is a well-recognized risk-factor for 
poor outcomes in pregnancy.31 In our series, three 
pregnancies occurred, resulting in good outcomes for 
both mother and child in two. However, in a third case, 
both mother and baby died during a Cesarean section in 
the severely anemic mother. Although this series of 3 is 
meager, a 33% mortality deserves close scrutiny to 
ensure better outcomes. 
 
Priapism, another potential cause that could impair 
reproductive competence, was rare in this series, rec-
orded in only 0.5% of males, a remarkably low inci-
dence when compared to other series. An international 
study of priapism in SCD demonstrated a prevalence of 
35% among males aged 4-66 years, with the earliest 
manifestation reported at age 12 years.32 Of 46 patients 
reporting priapism, 21% reported having erectile dys-
function. Why our series contained only one case is 
unclear, even though 62.5% of cases were 12 years and 
older. However, reluctance to report the symptom be-
cause of embarrassment could be a factor. A more rig-
orous attempt to determine the extent of priapism needs 
to be made in order to minimize improper management 
that could contribute to subsequent erectile dysfunc-
tion. 
 
Determining the cause of death in the 16 deaths has 
been difficult, principally because of the lack of autop-
sies. Nevertheless, using clinical information immedi-
ately before death, provisional causes could be as-
signed, bearing in mind, however, that autopsies re-
main the gold-standard for determining cause of death, 
especially in clinical studies. Nonetheless, with this 
proviso, the most frequent cause of death was “severe 
anemia,” accounting for or involved in 8 (50%) of the 
deaths, one of which was associated with pregnancy 
and delivery.  
 
The next most frequent cause of death was “bone pain 
crisis,” which was recorded for 2 patients. A transfu-
sion reaction that occurred during the transfusion of a 
second unit of blood after the uneventful transfusion of 
a prior unit for severe anemia was implicated in the 
death of one patient. 
 
The Kaplan-Meier 50% survival estimate, taken from 
the date of registration, could not be determined as it 
was too extended (Figure 2). The incidence of death, 
however, stands at 2.51 per 100 patient years. The ob-
servation period, at 637 patient-years is relatively short, 
but even so, this death incidence is extremely high 
when compared to other countries.23 If this alarming 
figure is confirmed, it would constitute a call for urgent 
action. Similarly, the mean survival time, estimated at 
slightly more than 3½ years emphasises the dire out-
look for SCD patients in this country. 
 
Many implications arise from this study. Firstly, the 
patients studied constitute a very narrow spectrum of 
SCD patients in the country. To know more about the 
nature of SCD in Sierra Leone, studies like the present 
one need to be repeated or expanded. Another im-
portant consideration is that our patients are young 
with relatively few adults in the cohort, which could be 
interpreted in a number of ways, including that SCD 
patients do not survive beyond early adulthood. Alt-
hough there might be an element of self-exclusion 
among the older patient, extremely high death inci-
dence in the cohort is consistent with a high rate of loss 
among SCD patients of all ages.  
 
Whatever the case, a formal examination needs to be 
carried out to obtain more reliable survival data. In 
addition, there is a need for better information about 
the clinical features of SCD and, especially, the risk 




Malaria has been implicated as a risk factor elsewhere 
on the continent,28 and there is, currently, debate about 
the role of bacterial infections, especially Streptococ-
cus pneumoniae, in morbidity and mortality in African 
SCD.29 Risk factors and causes of death in SCD are not 
 
 







known for this country in contrast to other African 
countries,33 so an improved method of death reporting 
up to and including autopsies is mandatory.  
 
That 50% of the deaths were attributable to anaemia, 
not treated with blood transfusion, signifies that access 
to blood transfusion services require upgrading. Simi-
larly, improved microbiological services are required to 
manage febrile illnesses appropriately and help in de-
fining preventive measures such as immunizations and 
chemoprophylaxis. It is of interest that the rates of 
complications seen in this study are much less than 
those observed when Knox-Macaulay studied SCD 
patients in the Freetown community thirty years ago.  
 
Why there are these differences is unknown, but since 
1983 there have been significant population shifts be-
cause of civil instability in spite of which, however, 
some beneficial changes in social amenities have oc-
curred. It is certainly relevant that patients followed in 
a clinic setting, where advice about sickle cell coping 
strategies is given, does have a beneficial effect on 
clinical outcomes.34 
 
Finally, there is no data relating to ethnic or regional 
patterns of SCD in the country, although it is likely that 
differences will be trivial. In any event, it would be 
important to establish gene frequencies and disease 
burden in the various districts in order to set priorities 
for service provision.  
 
CONCLUSION 
Although the challenges seem daunting, the best way to 
answer the questions this study has raised would be in 
a new-born screening study protocol in which all or the 
majority of new-borns with SCD in an area or district 
are identified and subsequently followed systematically 
and cared for in a structured way. Given the findings in 
our study, instituting such a protocol should be consid-
ered urgent.  
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